Ipilimumab / Nivolumab: 6 agencies, 2018–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 7.8 years, from 10 Dec 2018 at AWMSG (Wales) to 3 Sep 2026 at HIRA (South Korea).
HAS (France) changed its position: not recommended on 22 Nov 2023, recommended by 24 Sep 2025, after a resubmission.
No assessment is on file from SMC (Scotland), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 9 of 15 records date from 2023 or later.
7 distinct indication wordings are recorded for ipilimumab / nivolumab by the agencies that label one in English (AWMSG, NICE and PBAC).
5 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess ipilimumab / nivolumab, on 10 Dec 2018; HIRA (South Korea) did not open a file until 3 Sep 2026 — a wide spread of 7.8 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 7 years in total.
4 of the 6 agencies here assessed ipilimumab / nivolumab more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for ipilimumab / nivolumab.
The full ledger for ipilimumab / nivolumab reads 7 recommended, 3 not recommended, 2 deferred to NICE and 1 appraised, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 23 Feb 2026 | Mesothelioma, unresectable, malignant (sarcomatoid or biphasic subtypes) | PTAC advice: Medium | source |
| NICE (England) | 28 May 2025 | NICE TA1065 | published appraisal | source |
| HAS (France) | 22 Nov 2023 | Indication extension | SMR insufficient · ASMR III | source |
| AWMSG (Wales) | 30 Apr 2021 | Treatment of metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | excluded, NICE appraised | source |
| PBAC (Australia) | 2020 | Non-small cell lung cancer (NSCLC) | The PBAC recommendation cannot be made public until the TGA outcome is known. | source |
10 further decisions for ipilimumab / nivolumab, across 5 agencies, are not shown here. They include the most recent record on file, 3 Sep 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 4 further source documents.
Related molecules
- sotorasib — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
Coverage: 15 decisions for ipilimumab / nivolumab from 6 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.